ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immunoglobulins

Also written as “IgPro10”, “TAK-771” and “Immunoglobulins Intravenous (Human)”.

Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Agammaglobulinemia · Scleroderma, Diffuse · Purpura, Thrombocytopenic, Idiopathic, led by 4 companies.

Drug pageImmunoglobulins: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 7, 201119 company-led studies, 2 open or runningNext primary completion: Dec 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSLits history only111 open or runningphase 4since Jul 7, 2011Sep 12, 2005Dec 20, 2029phase 4 · NCT03684018
Takeda60 open or runningphase 3since Sep 11, 2015Sep 11, 2015none ahead
GC Biopharmaits history only10 open or runningphase 3since Feb 19, 2018Feb 19, 2018none ahead
Kedrionits history only11 open or runningphase 3since Dec 16, 2024Dec 16, 2024Dec 20, 2027phase 3 · NCT06752356

Also a collaborator on its studies: Takeda Development Center Americas.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2015First study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingFirst studyNCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
  2. Apr 10, 2020Phase 3 study in Primary Immunodeficiency DiseasesNCT04346108 · 17 enrolled · Japan
  3. Apr 11, 2021Phase 3 study in Primary Immunodeficiency DiseasesNCT04842643 · 12 enrolled · Japan
  4. Oct 10, 2021Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT05084053 · 26 enrolled · Japan
  5. Nov 24, 2021Phase 3 study in Primary Immunodeficiency DiseasesNCT05150340 · 16 enrolled · Japan
  6. Aug 22, 2022Phase 3 study in Primary Immunodeficiency DiseasesNCT05513586 · 15 enrolled · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05513586Primary Immunodeficiency Diseases · Japan3CompletedOct 30, 202515
NCT05150340Primary Immunodeficiency Diseases · Japan3CompletedAug 28, 202316
NCT05084053Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan3CompletedOct 28, 202526
NCT04842643Primary Immunodeficiency Diseases · Japan3CompletedApr 25, 202412
NCT04346108Primary Immunodeficiency Diseases · Japan3CompletedDec 22, 202117
NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more3CompletedFeb 23, 2022138

How it is read

Names in the registry

  • “IgPro10”, 4 entries
  • “TAK-771”, 3 entries
  • “Immunoglobulins Intravenous (Human)”, 3 entries
  • “Immunoglobulin”, 2 entries
  • “Immune globulin (human) 10% solution for intravenous administration”, 1 entry

Codes read as this program: IGPRO10.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.